Model Medicines Presented to Investors at Wells Fargo’s Private Biotech Symposium
Events
Patrick ONeill
Model Medicines participated in Wells Fargo’s Private Biotech Symposium, where company leadership met virtually with biotech investors to discuss the company’s expanding oncology pipeline and AI-driven discovery platform.
Patrick ONeill
Head of Partnerships and Investor Relations
Model Medicines participated in the Wells Fargo Private Biotech Symposium on November 2, 2022, engaging investors through a series of virtual one-on-one meetings. The event followed the company’s announcement of oncology programs targeting AXL and BRD4, marking an important expansion of Model Medicines’ pipeline beyond infectious disease.
The symposium gave company leadership an opportunity to share Model Medicines’ broader platform strategy, including how GALILEO™ was being applied to identify novel chemistry against high-value therapeutic targets. For investors, the meetings offered a closer look at the company’s evolution into a multi-program, AI-driven biotech advancing differentiated therapeutic candidates across areas of significant unmet need.
